Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Insulin degludec plus liraglutide

Brand: Xultophy®
NICE TA: 
Indication: Treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control, in combination with oral glucose-lowering medicinal products when these alone, or combined with basal insulin, do not provide adequate glycaemic control
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: No

Background

The combination product insulin degludec plus liraglutide (Xultophy®▼) is not recommended to treat type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone, or combined with basal insulin, do not adequately provide glycaemic control.

Recommendation

LMMG recommendation: Black
Click here to find the definitions for the colour classifications

Reason for decision:  Not recommended for prescribing on the NHS in Lancashire

Supporting documents:

LMMG New Medicine Recommendation - Xultophy

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Black

Black

Black

Black

Black

Black